A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosquera Orgueira, Adrián, Díaz Arías, Jose Ángel, Serrano Martín, Rocio, Portela Piñeiro, Victor, Cid López, Miguel, Peleteiro Raíndo, Andrés, Bao Pérez, Laura, González Pérez, Marta Sonia, Pérez Encinas, Manuel Mateo, Fraga Rodríguez, Máximo Francisco, Vallejo Llamas, Juan Carlos, Bello López, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175759/
https://www.ncbi.nlm.nih.gov/pubmed/37188190
http://dx.doi.org/10.3389/fonc.2023.1157646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175759/
https://www.ncbi.nlm.nih.gov/pubmed/37188190
http://dx.doi.org/10.3389/fonc.2023.1157646

Ejemplares similares